Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
No open-market purchases or sales by Vor Biopharma Inc. insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q3 2026, worth $1.06B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $1.18B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +55 vs. previous quarter
- 155
- 13F valueReported value at the end of Q3 2026
- $1.06B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$696.0M
- No comparable prior period
- Free cash flow, FY2025
- -$143.7M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.50M
- Shares sold short
- Change
- +58.9K
- +0.8% vs. previous
- Days to cover
- 9.88
- At average daily volume
Superinvestors holding VOR, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding VOR at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Vor Biopharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 (view filing)4:54 PM ET | Jul 16 | 5 daysLate | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −213 | $19.75 | −$4.21K | 0.0%4.50M after | |
| Apr 24, 2026 (view filing)6:12 PM ET | Apr 22 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −165.2K | $15.77 | −$2.60M | −6.4%2.40M after | |
| Apr 21, 2026 (view filing)7:04 PM ET | Apr 17-20 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −630.4K | $16.14 | −$10.2M | −19.7%2.57M after | 2 lots |
| Apr 15, 2026 (view filing)5:29 PM ET | Apr 13-15 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −738.0K | $16.10 | −$11.9M | −18.8%3.20M after | 3 lots |
| Apr 10, 2026 (view filing)6:23 PM ET | Apr 8-10 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −620.1K | $16.50 | −$10.2M | −13.6%3.94M after | 4 lots |
| Apr 6, 2026 (view filing)6:51 PM ET | Apr 2-6 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −849.3K | $17.10 | −$14.5M | −15.7%4.56M after | 5 lots |
| Oct 30, 2025 (view filing)6:40 PM ET | Oct 28-30 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −400.4K | $25.90 | −$10.4M | −33.9%779.7K after | 4 lots |
| Oct 27, 2025 (view filing)8:04 PM ET | Oct 23-27 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −221.2K | $28.06 | −$6.20M | −15.8%1.18M after | 3 lots |
| Oct 22, 2025 (view filing)7:48 PM ET | Oct 20-21 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | SSale | −117.0K | $29.34 | −$3.43M | −7.7%1.40M after | 5 lots |
| Oct 21, 2025 (view filing)5:45 PM ET | Oct 17-21 | 4 days | Hoffman Reid and 1 other10% Owner | SSale | −37.5K | $30.19 | −$1.13M | −3.1%1.17M after | 4 lots |
Top 10 13F holders, Q3 2026
See all 155 holdersThe largest institutional positions in Vor Biopharma Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 6,759,007 | $129.0M | 0.01% | +1,826,858+37.0% | Added |
| TCG Crossover Management, LLC | 5,673,078 | $108.2M | 3.06% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,503,882 | $85.9M | 0.86% | +2,101,787+87.5% | Added |
| FCPM III Services B.V. | 3,405,279 | $65.0M | 6.13% | −712,075−17.3% | Reduced |
| BlackRock, Inc. | 3,306,494 | $63.1M | 0.00% | −161,613−4.7% | Reduced |
| VR Adviser, LLC | 3,041,719 | $58.0M | 2.82% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 2,743,939 | $52.4M | 1.30% | +200,000+7.9% | Added |
| Vanguard Capital Management LLC | 2,035,477 | $38.8M | 0.00% | −48,851−2.3% | Reduced |
| State Street Corp | 1,969,801 | $37.6M | 0.00% | −646,535−24.7% | Reduced |
| Caligan Partners LP | 1,925,066 | $36.7M | 2.25% | 00.0% | Unchanged |
Holders of 5% or more of VOR
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Vor Biopharma Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 19.90%12.9M shares | 0.00 ppfrom 19.90% | Feb 19, 202119 filings | Jul 21, 2026 | SEC |
| Reprogrammed Interchange LLC | 13D/A | 17.60%1.20M shares | −1.00 ppfrom 18.60% | Jan 7, 20259 filings | Oct 17, 2025 | SEC |
| FMR LLC | 13G/A | 10.70%6.32M shares | −1.30 ppfrom 12.00% | Nov 7, 20256 filings | Nov 5, 2026 | SEC |
| ForGrowth III PA B.V. | 13D | 9.99%10.2M shares | 0.00 ppfrom 9.99% | Sep 23, 20252 filings | Dec 23, 2025 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.90%6.44M shares | 0.00 ppfrom 9.90% | Sep 25, 20255 filings | Nov 16, 2026 | SEC |